Contineum Therapeutics (CTNM) Announces Proposed IPO

Contineum Therapeutics (NASDAQ: CTNM) has filed for a proposed Nasdaq IPO.

The company describes itself as: "We are a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications with high unmet need."

Goldman Sachs & Co, Morgan Stanley, Stifel and RBC Capital Markets will serve as lead underwriters.

You May Also Be Interested In

• OpenAI revenue chief quits after less than a year
• Stifel Reiterates Buy Rating on Coherent (COHR)
• Adamas Trust prices $90M senior notes offering at 9.600%